Skip to main content
SpringerLink
Log in

Future Directions in the Management of Rhino-Orbito-Cerebral Mucormycosis

  • Chapter
  • First Online:
Rhino-Orbito-Cerebral Mucormycosis

  • 307 Accesses

Abstract

There are several unmet needs in managing rhino-orbito-cerebral mucormycosis (ROCM), especially once the mucormycosis has spread to the brain. Based on the experience of dealing with various situations during ROCM outbreak this chapter outlines those problems and make recommendations for future research. Various parameters described here include quick and reliable diagnostic tests, including PCR and molecular tests, and decision making about the extent of surgical debridement. Some of the problems include the need to find the ideal antifungal drug, drug resistance/Minimal Inhibitory Concentration/drug susceptibility, duration of antifungal drugs, combination antifungal drugs, and the high cost of antifungal drugs. The future lies in solving the challenges that lie ahead.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi. 2019;5:59. https://doi.org/10.3390/jof5030059.

    Article  CAS  Google Scholar 

  2. Dadwal SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn. 2018;18:845–54.

    Article  CAS  Google Scholar 

  3. Schelenz S, Barnes RA, Barton RC, Cleverley JR, Lucas SB, Kibbler CC, Denning DW. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis. 2015;15:461–74.

    Article  Google Scholar 

  4. Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T, Gu Y, Bruno VM, Cornely OA, Leather HL, Sugrue MW, et al. PCR-based approach targeting mucorales-specific gene family for diagnosis of mucormycosis. J Clin Microbiol. 2018;56:e00746–18.

    Article  CAS  Google Scholar 

  5. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–21.

    Article  CAS  Google Scholar 

  6. Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P, Kaur H, et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J Med Microbiol. 2017;66(8):1124–9.

    Article  CAS  Google Scholar 

  7. Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85(1009):573–81.

    Article  CAS  Google Scholar 

  8. Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al. Ten Years’ experience in zygomycosis at a tertiary care centre in India. J Infect. 2001;42(4):261–6.

    Article  CAS  Google Scholar 

  9. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335–42.

    Article  Google Scholar 

  10. Jung J, Park YS, Sung H, Song JS, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Using immunohistochemistry to assess the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis. Clin Infect Dis. 2015;61:1664–70.

    CAS  PubMed  Google Scholar 

  11. Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis. 2013;56(10):e95–101.

    Article  CAS  Google Scholar 

  12. Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016;22(9):810.e1–8.

    Article  CAS  Google Scholar 

  13. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of Mucormycosis: an update. J Fungi (Basel). 2020;6(4):265.

    Article  CAS  Google Scholar 

  14. Guegan H, Iriart X, Bougnoux M-E, Berry A, Robert-Gangneux F, Gangneux J-P. Evaluation of MucorGenius® mucorales PCR assay for the diagnosis of pulmonary mucormycosis. J Infect. 2020;81(2):311–7.

    Article  CAS  Google Scholar 

  15. Caillot D, Valot S, Lafon I, Basmaciyan L, Chretien ML, Sautour M, et al. Is it time to include CT “reverse halo sign” and qPCR targeting mucorales in serum to EORTC-MSG criteria for the diagnosis of pulmonary mucormycosis in leukemia patients? Open Forum Infect Dis. 2016;3(4):ofw190.

    Article  Google Scholar 

  16. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.

    Article  Google Scholar 

  17. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O, French Mycosis Study Group. A global analysis of mucormycosis in France: the retro zygo study (2005–2007). Clin Infect Dis. 2012;54:S35–43.

    Article  CAS  Google Scholar 

  18. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67.

    Article  CAS  Google Scholar 

  19. Kasapoglu F, Coskun H, Ozmen OA, Akalin H, Ener B. Acute invasive fungal rhinosinusitis: evaluation of 26 patients treated with endonasal or open surgical procedures. Otolaryngol Head Neck Surg. 2010;143:614–20.

    Article  Google Scholar 

  20. Gillespie MB, O'Malley BW Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg. 1998;124:520–6.

    Article  CAS  Google Scholar 

  21. Davoudi S, Kumar VA, Jiang Y, Kupferman M, Kontoyiannis DP. Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-Centre study. J Antimicrob Chemother. 2015;70:2899–905.

    Article  CAS  Google Scholar 

  22. Turner JH, Soudry E, Nayak JV, Hwang PH. Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence. Laryngoscope. 2013;123:1112–8.

    Article  Google Scholar 

  23. Zuniga MG, Turner JH. Treatment outcomes in acute invasive fungal rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2014;22:242–8.

    Article  Google Scholar 

  24. Ben-Ami R, Halaburda K, Klyasova G, Metan G, Torosian T, Akova M. A multidisciplinaryteam approach to the management of patients with suspected or diagnosed invasive fungal disease. J Antimicrob Chemother. 2013;68:iii25–33.

    Article  CAS  Google Scholar 

  25. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371:150–60.

    Article  Google Scholar 

  26. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, Mitroussia-Ziouva A, Tsakris A, Petrikkos G. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67(8):1937–40. https://doi.org/10.1093/jac/dks137.

    Article  CAS  PubMed  Google Scholar 

  27. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.

    Article  CAS  Google Scholar 

  28. Arikan S, Sancak B, Alp S, et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol. 2008;46:567–73.

    Article  CAS  Google Scholar 

  29. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against aspergillus spp. and fusarium spp. Antimicrob Agents Chemother. 2005;49:3572–4.

    Article  CAS  Google Scholar 

  30. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against aspergillus and fusarium spp. Antimicrob Agents Chemother. 2002;46:245–7.

    Article  CAS  Google Scholar 

  31. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivityof amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989;33:362–8.

    Article  CAS  Google Scholar 

  32. Collette N, Van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution andbioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother. 1991;27:535–48.

    Article  CAS  Google Scholar 

  33. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274–82.

    Article  CAS  Google Scholar 

  34. Grannan BL, Yanamadala V, Venteicher AS, Walcott BP, Barr JC. Use of external ventriculostomy and intrathecal antifungal treatment in cerebral mucormycotic abscess. J Clin Neurosci. 2014;21:1819–21.

    Article  Google Scholar 

  35. Lamoth F, Mercier T, Andre P, Pagani JL, Pantet O, Maduri R, Guery B, Decosterd LA. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother. 2019;74:1751–3.

    Article  CAS  Google Scholar 

  36. Schmitt-Hoffmann AH, Kato K, Townsend R, Potchoiba MJ, Hope WW, Andes D, Spickermann J, Schneidkraut MJ. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats. Antimicrob Agents Chemother. 2017;61:e01292–17.

    Article  CAS  Google Scholar 

  37. Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant. 2009;44:269–70.

    Article  CAS  Google Scholar 

  38. Ruping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Muller C, Vehreschild JJ, Kochanek M, Fatkenheuer G, Bangard C, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother. 2008;62:1468–70.

    Article  Google Scholar 

  39. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D’Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. Antimicrob Chemother. 2011;66:224–5.

    Article  CAS  Google Scholar 

  40. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56:745–55.

    Article  CAS  Google Scholar 

  41. Tarani L, Costantino F, Notheis G, Wintergerst U, Venditti M, Di Biasi C, Friederici D, Pasquino AM. Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatr Diabetes. 2009;10:289–93.

    Article  Google Scholar 

  42. Davoudi S, Anderlini P, Fuller GN, Kontoyiannis DP. A long-term survivor of disseminated aspergillus and mucorales infection: an instructive case. Mycopathologia. 2014;178:465–70.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr Shroff’s Charity Eye Hospital, New Delhi, India

    Nishi Gupta

Authors
  1. Nishi Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Otorhinolaryngology & Head & Neck Surgery, Dr Shroff Charity Eye Hospital, Daryaganj, Delhi, India

    Nishi Gupta

  2. Department of Ophthalmic Plastic Surgery and Orbital Diseases, Centre for Sight, Banjara Hills, Hyderabad, India

    Santosh G. Honavar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gupta, N. (2022). Future Directions in the Management of Rhino-Orbito-Cerebral Mucormycosis. In: Gupta, N., Honavar, S.G. (eds) Rhino-Orbito-Cerebral Mucormycosis. Springer, Singapore. https://doi.org/10.1007/978-981-16-9729-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-9729-6_23

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-9728-9

  • Online ISBN: 978-981-16-9729-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation